[go: up one dir, main page]

MX9301527A - Composiciones de acido n-(fosfonoacetil)-l-aspartico y metodo para sus usos como agentes antivirales de amplio espectro. - Google Patents

Composiciones de acido n-(fosfonoacetil)-l-aspartico y metodo para sus usos como agentes antivirales de amplio espectro.

Info

Publication number
MX9301527A
MX9301527A MX9301527A MX9301527A MX9301527A MX 9301527 A MX9301527 A MX 9301527A MX 9301527 A MX9301527 A MX 9301527A MX 9301527 A MX9301527 A MX 9301527A MX 9301527 A MX9301527 A MX 9301527A
Authority
MX
Mexico
Prior art keywords
compositions
phosphonocezyl
antiviral agents
aspartic acid
broad spectrum
Prior art date
Application number
MX9301527A
Other languages
English (en)
Inventor
Herbert A Blough
Original Assignee
Us Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/032,234 external-priority patent/US5491135A/en
Application filed by Us Bioscience Inc filed Critical Us Bioscience Inc
Publication of MX9301527A publication Critical patent/MX9301527A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composiciones y métodos se presentan y utilizan la actividad antiviral de amplio espectro de PALA. Este compuesto y sus análogos farmacéuticamente aceptable poseen una actividad potente mientras que presentan una toxicidad mínima y por consiguiente, se caracterizan por un índice terapéutico relativamente alto. Las composiciones que contienen otros agentes terapéuticos, tales como otros agentes antivirales, se presentan también y poseen actividades antivirales adicionales y/o sinergísticas.
MX9301527A 1992-03-18 1993-03-18 Composiciones de acido n-(fosfonoacetil)-l-aspartico y metodo para sus usos como agentes antivirales de amplio espectro. MX9301527A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85345492A 1992-03-18 1992-03-18
US08/032,234 US5491135A (en) 1992-03-18 1993-03-17 Compositions of N-(phosphonoacetyl)-L-aspartic acid and methods of their use as broad spectrum antivirals

Publications (1)

Publication Number Publication Date
MX9301527A true MX9301527A (es) 1994-02-28

Family

ID=26708159

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9301527A MX9301527A (es) 1992-03-18 1993-03-18 Composiciones de acido n-(fosfonoacetil)-l-aspartico y metodo para sus usos como agentes antivirales de amplio espectro.

Country Status (10)

Country Link
EP (1) EP0660710A1 (es)
JP (1) JPH07507770A (es)
CN (1) CN1080853A (es)
AU (1) AU3965993A (es)
BR (1) BR9306123A (es)
CA (1) CA2109435C (es)
IL (1) IL105090A (es)
IS (1) IS3987A (es)
MX (1) MX9301527A (es)
WO (1) WO1993018763A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440980B1 (en) * 1996-09-17 2002-08-27 Avanir Pharmaceuticals Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
US20030100532A1 (en) 1997-02-14 2003-05-29 Gary S. Jacob Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy for treating hepatitis virus infections
ES2216327T3 (es) 1997-11-10 2004-10-16 G.D. SEARLE & CO. Uso de iminoazucares alquilados para tratar la resistencia a multiples a farmacos.
BR9907882A (pt) 1998-02-12 2000-10-17 Searle & Co Uso de compostos de 1,5-didesóxi-1,5-imino-d-glucitol n-substituìdos para o tratamento de infecções de vìrus de hepatite
US6689759B1 (en) 1998-02-12 2004-02-10 G. D. Searle & Co. Methods of Treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy
DE60039729D1 (de) 1999-02-12 2008-09-11 United Therapeutics Corp N-(8,8,8-Trifluorooctyl)-1,5-dideoxy-1,5-imino-D-glucitol zur Behandlung von Hepatitis-Virus-Infektionen
WO2001008672A2 (en) 1999-02-12 2001-02-08 G.D. Searle & Co. Glucamine compounds for treating hepatitis virus infections
WO2001045727A2 (en) * 1999-12-20 2001-06-28 New Pharma Research Sweden Ab Stabilized veterinary compositions comprising more than one antiviral agent
DE10138912A1 (de) * 2001-08-08 2003-02-27 Medinnova Ges Med Innovationen Verwendung von Wirksubstanzen zur Prophylaxe und/oder Therapie von Viruserkrankungen sowie Testsystem zum Auffinden solcher Wirksubstanzen
DE10343365A1 (de) * 2003-09-17 2005-04-14 Biosphings Ag Pharmazeutische Formulierungen von Xanthogenaten und Hemmstoffen der viralen Nukleinsäurereplikation
US8236768B2 (en) 2008-10-03 2012-08-07 3B Pharmaceuticals, Inc. Topical antiviral formulations
CN111317733B (zh) * 2020-03-24 2022-07-12 中国人民解放军海军军医大学 利福霉素类抗生素在制备抗黄热病毒感染药物中的应用
WO2021189444A1 (zh) * 2020-03-24 2021-09-30 中国人民解放军海军军医大学 利福霉素类抗生素在制备抗黄热病毒感染药物中的应用
CN111419839A (zh) * 2020-03-31 2020-07-17 远见生物科技（上海）有限公司 利福霉素的新用途
EP4162952A4 (en) * 2020-04-30 2024-08-21 Kyoto University PROPHYLACTIC OR THERAPEUTIC AGENT FOR RNA VIRUS-RELATED DISEASES
WO2022200615A1 (en) * 2021-03-26 2022-09-29 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Pyrimidine biosynthesis inhibitor combination for use in treating viral infections

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4178306A (en) * 1978-08-10 1979-12-11 Parsons Jack L Preparation of N-(phosphonoacetyl)-L-aspartic acid

Also Published As

Publication number Publication date
EP0660710A1 (en) 1995-07-05
IS3987A (is) 1993-09-19
JPH07507770A (ja) 1995-08-31
AU3965993A (en) 1993-10-21
WO1993018763A1 (en) 1993-09-30
CA2109435A1 (en) 1993-09-19
CN1080853A (zh) 1994-01-19
IL105090A0 (en) 1994-08-26
EP0660710A4 (en) 1995-03-02
IL105090A (en) 1998-08-16
BR9306123A (pt) 1997-08-26
CA2109435C (en) 1997-03-11

Similar Documents

Publication Publication Date Title
MX9301527A (es) Composiciones de acido n-(fosfonoacetil)-l-aspartico y metodo para sus usos como agentes antivirales de amplio espectro.
NZ208529A (en) 2-pyrimidinyl-1-piperazine derivatives and pharmaceutical compositions
ES2104946T3 (es) Ureas ciclicas y similares utiles como inhibidores de la proteasa retrovirica.
RU95113454A (ru) Катехольные диэфиры как селективные ингибиторы фдэiv, фармацевтическая композиция, способы лечения
BR9305907A (pt) Uso de derivados de substituída para tratamento de esclerose múltipla
EP0201742A3 (en) N-acylpyrrolidine derivatives, processes for preparing them, pharmaceutical composition and use
IT1230742B (it) Composizione per aerosol comprendente nitroglicerina come ingrediente attivo.
ES2126766T3 (es) 7-azaindol-3-ilcarboxiamidas de tropilo como agente antitusivo.
ES2066781T3 (es) Nuevas n-(1-alquil-3-hidroxi-4-piperidinil)-benzamidas sustituidas.
ES2179996T3 (es) Cefalosporinas de vinil-pirrolidinona con sustituyentes basicos.
AU6319480A (en) 2-hydroxyalkyl-3,4,5-trihydroxypiperidines
AP9300561A0 (en) Antibiotic compounds.
NZ241099A (en) Difluorostatone analogues and derivatives and pharmaceutical compositions
PT861250E (pt) Derivados de amidina e de isotioureia como inibidores de oxido nitrico sintase
CA2100066A1 (en) Michellamines useful as antiviral agents, composition and method of treatment
AR247327A1 (es) Una composicion herbicida
ES2086528T3 (es) Nuevos compuestos biciclicos sustituidos con amino.
AU581855B2 (en) 1-(4'-alkylsulphonylphenyl)-2-amino-1, 3-propanediol n-substituted derivatives
ES2065855B1 (es) Procedimiento para la preparacion de nuevos derivados desoxiazafosfolipidicos con accion inhibidora de la fosfolipasa a2, nuevos derivados desoxiazafosfolipidicos obtenidos y utilizacion de los mismos.
AU581856B2 (en) 1-(4'-alkylthiophenyl)-2-amino-1, 3-propanediol N-substituted derivatives
GB1433227A (en) Dibenzazecines and pharmaceutical uses thereof
EP0414903A4 (en) New thioproline derivative
ES2054790T3 (es) Compuestos que tienen actividad cardiovascular.
ES2126923T3 (es) 8-fluoro-antraciclinas, procedimientos para su preparacion y composiciones farmaceuticas que las contienen.
ES2139159T3 (es) Pseudopeptidos derivados de neuroquininas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.